0625 GMT - Concerns about Roche's upcoming clinical trial results persist despite improvements in its midstage pipeline over the past year, Berenberg analysts say in a note. The Swiss drugmaker's higher implemented threshold in assessing drug candidates should begin to shift the mix of its late-stage readouts toward higher return-on-investment assets, the analysts say. Berenberg analysts are less optimistic about Roche's key clinical results this year, seen as high-risk as they started before the company launched initiatives aimed at improving R&D decision-making. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
May 02, 2025 02:25 ET (06:25 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.